Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
By Sonia S Anand, J. Bosch, J. Eikelboom, S. Connolly, Co-Principle Investigators. The Lancet, 2018
696 citations recorded by the source corpus.
View Paper: https://www.semanticscholar.org/paper/af705d340539758c05004e20b5429bd9700e2fc2
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- M. Conte
- A. Bradbury
- D. Armstrong
- V. Aboyans
- J. Mills
- F. Pomposelli
- P. Kolh
- John V. White
Citations in the corpus
- Global vascular guidelines on the management of chronic limb-threatening ischemia (2019, methodology): “The Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial, a multicenter randomized trial of 7470 individuals with stable, mild to moderate PAD, found that low-dose rivaroxaban (an oral factor Xa inhibitor) in combination with aspirin reduced MACEs (death, myocardial in”